IBDEI0HD ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8438,1,4,0)
 ;;=4^369.12
 ;;^UTILITY(U,$J,358.3,8438,2)
 ;;=^268872
 ;;^UTILITY(U,$J,358.3,8439,0)
 ;;=369.13^^58^609^80
 ;;^UTILITY(U,$J,358.3,8439,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8439,1,3,0)
 ;;=3^One Eye-Severe/Oth Eye-Near Total
 ;;^UTILITY(U,$J,358.3,8439,1,4,0)
 ;;=4^369.13
 ;;^UTILITY(U,$J,358.3,8439,2)
 ;;=^268873
 ;;^UTILITY(U,$J,358.3,8440,0)
 ;;=369.14^^58^609^81
 ;;^UTILITY(U,$J,358.3,8440,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8440,1,3,0)
 ;;=3^One Eye-Severe/Oth Eye-Profound
 ;;^UTILITY(U,$J,358.3,8440,1,4,0)
 ;;=4^369.14
 ;;^UTILITY(U,$J,358.3,8440,2)
 ;;=^268874
 ;;^UTILITY(U,$J,358.3,8441,0)
 ;;=369.22^^58^609^102
 ;;^UTILITY(U,$J,358.3,8441,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8441,1,3,0)
 ;;=3^Severe Impairment,Both Eyes
 ;;^UTILITY(U,$J,358.3,8441,1,4,0)
 ;;=4^369.22
 ;;^UTILITY(U,$J,358.3,8441,2)
 ;;=^268882
 ;;^UTILITY(U,$J,358.3,8442,0)
 ;;=369.60^^58^609^6
 ;;^UTILITY(U,$J,358.3,8442,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8442,1,3,0)
 ;;=3^Blindness,One Eye Only
 ;;^UTILITY(U,$J,358.3,8442,1,4,0)
 ;;=4^369.60
 ;;^UTILITY(U,$J,358.3,8442,2)
 ;;=^268880
 ;;^UTILITY(U,$J,358.3,8443,0)
 ;;=369.9^^58^609^115
 ;;^UTILITY(U,$J,358.3,8443,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8443,1,3,0)
 ;;=3^Visual Loss NOS
 ;;^UTILITY(U,$J,358.3,8443,1,4,0)
 ;;=4^369.9
 ;;^UTILITY(U,$J,358.3,8443,2)
 ;;=^126769
 ;;^UTILITY(U,$J,358.3,8444,0)
 ;;=377.61^^58^609^20
 ;;^UTILITY(U,$J,358.3,8444,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8444,1,3,0)
 ;;=3^D/O Pathways w/ Neoplasm
 ;;^UTILITY(U,$J,358.3,8444,1,4,0)
 ;;=4^377.61
 ;;^UTILITY(U,$J,358.3,8444,2)
 ;;=^269241
 ;;^UTILITY(U,$J,358.3,8445,0)
 ;;=379.02^^58^609^68
 ;;^UTILITY(U,$J,358.3,8445,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8445,1,3,0)
 ;;=3^Nodular Episcleritis
 ;;^UTILITY(U,$J,358.3,8445,1,4,0)
 ;;=4^379.02
 ;;^UTILITY(U,$J,358.3,8445,2)
 ;;=^269285
 ;;^UTILITY(U,$J,358.3,8446,0)
 ;;=379.07^^58^609^90
 ;;^UTILITY(U,$J,358.3,8446,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8446,1,3,0)
 ;;=3^Posterior Scleritis
 ;;^UTILITY(U,$J,358.3,8446,1,4,0)
 ;;=4^379.07
 ;;^UTILITY(U,$J,358.3,8446,2)
 ;;=^269295
 ;;^UTILITY(U,$J,358.3,8447,0)
 ;;=379.92^^58^609^106
 ;;^UTILITY(U,$J,358.3,8447,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8447,1,3,0)
 ;;=3^Swelling/Mass of Eye
 ;;^UTILITY(U,$J,358.3,8447,1,4,0)
 ;;=4^379.92
 ;;^UTILITY(U,$J,358.3,8447,2)
 ;;=^269334
 ;;^UTILITY(U,$J,358.3,8448,0)
 ;;=379.93^^58^609^94
 ;;^UTILITY(U,$J,358.3,8448,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8448,1,3,0)
 ;;=3^Redness/Discharge of Eye
 ;;^UTILITY(U,$J,358.3,8448,1,4,0)
 ;;=4^379.93
 ;;^UTILITY(U,$J,358.3,8448,2)
 ;;=^104154
 ;;^UTILITY(U,$J,358.3,8449,0)
 ;;=379.99^^58^609^86
 ;;^UTILITY(U,$J,358.3,8449,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8449,1,3,0)
 ;;=3^Oth Ill-Defined Eye D/O
 ;;^UTILITY(U,$J,358.3,8449,1,4,0)
 ;;=4^379.99
 ;;^UTILITY(U,$J,358.3,8449,2)
 ;;=^269335
 ;;^UTILITY(U,$J,358.3,8450,0)
 ;;=555.9^^58^609^95
 ;;^UTILITY(U,$J,358.3,8450,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8450,1,3,0)
 ;;=3^Regional Enteritis,Unspec
 ;;^UTILITY(U,$J,358.3,8450,1,4,0)
 ;;=4^555.9
 ;;^UTILITY(U,$J,358.3,8450,2)
 ;;=^29356
 ;;^UTILITY(U,$J,358.3,8451,0)
 ;;=696.1^^58^609^93
 ;;^UTILITY(U,$J,358.3,8451,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8451,1,3,0)
 ;;=3^Psoriasis
 ;;^UTILITY(U,$J,358.3,8451,1,4,0)
 ;;=4^696.1
 ;;^UTILITY(U,$J,358.3,8451,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,8452,0)
 ;;=709.2^^58^609^39
 ;;^UTILITY(U,$J,358.3,8452,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8452,1,3,0)
 ;;=3^Facial Scar
